Healthcare
Sera Prognostics, Inc.(SERA)
Live Price
Offline$1.87
-3.11% today
1Y Change
-0.53%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +5.2%
- EPS Growth
- +32.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sera Prognostics, Inc. (SERA) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $1.87 and down 0.5% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +5.2%, EPS growth of +32.3%, a dividend yield of 0.0%. What stands out right now is revenue +5.2%, EPS +32.3%, free cash flow -72.3% with operating margin -45066.7% and ROIC -47.0%. Valuation already assumes a fairly strong business story at price/sales 900.6. Stock Foundry combines SERA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.2% vs +7.6% peer median
Operating Margin
Below sector median
-45066.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +5.2% and EPS at +32.3%, with operating margin around -45066.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +6.1% | -12.2% | +24.0% |
2026 Mar 18, 2026 | +5.9% | -6.3% | +4.2% | +23.0% |
2025 Nov 13, 2025 | +15.8% | +0.3% | +6.1% | +19.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SERA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SERA Max Drawdown
-61.12%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SERA and SPY.
Company Overview
Sera Prognostics, Inc.
NASDAQ Global Market
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
- Leadership
- Zhenya Lindgardt
- IPO Date
- Jul 15, 2021
- Employees
- 63
- Street Address
- 2749 East Parleys Way
- Mailing
- Salt Lake City, UT, 84109
- Region
- Salt Lake City, UT, US
- Reporting Currency
- USD
- Investor Line
- 801 990 0520
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 900.6
- Price/Book
- 1.3
Growth
- Revenue
- +5.2%
- EPS
- +32.3%
- Free Cash Flow
- -72.3%
Profitability
- Gross Margin
- -102.5%
- Operating Margin
- -45066.7%
- Net Margin
- -39417.3%
- ROE
- -37.5%
- ROIC
- -47.0%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 1.69
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.